KIM-1 levels are elevated in ccRCC patients and BRTKIM-1 levels could discriminate ccRCC at all stages: Stage I: 81% sensitivity; Stage II-IV: 97% sensitivityKIM-1 levels correlated with tumor stage (stage 1/2 vs. stage 3/4). This evidence concerns the gene HAVCR1 and neoplasm.